Abstract
Psoriasis vulgaris is a common HLA-associated chronic, inflammatory disease of the skin and partly also of the connective tissue in the form of psoriatic arthritis. Psoriasis develops because of a complex genetic predisposition and has a familial occurrence that is often detectable over generations. Psoriasis also occurs without family background and known genetic associations. The skin lesions of psoriasis are sharply defined, silvery-white scaly erythematosquamous plaques in typical distribution. They result from increased inflammatory epidermopoiesis and can cover wide areas of the skin. In addition to the classic skin manifestations such as guttate psoriasis or plaque psoriasis, there are various generalized or localized special forms with or without pustules. A substantial number of psoriasis patients develop seronegative polyarthritis. Diseases frequently associated with psoriasis are inflammatory bowel disease and uveitis. Depending on its duration and severity, psoriasis also involves an independent risk of obesity, metabolic syndrome, cardiovascular disease, and increased mortality. Psoriasis is now considered to be a predominantly T-cell-mediated autoimmune disease in which activation of a certain functional type of autoreactive T cells against skin tissue cells causes chronic inflammation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Psoriasis Vulgaris with Subforms
Arakawa A, Siewert K, Stöhr J et al (2015) Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 212:2203–2212
Brandrup F, Holm N, Grunnet N et al (1982) Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 62:229–236
Cargill M, Schrodi SJ, Chang M et al (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80:273–290
Farber EM, Nall ML, Watson W (1974) Natural history of psoriasis in 61 twin pairs. Arch Dermatol 109:207–210
Gelfand JM, Neimann AL, Shin DB et al (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741
Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, Spencer CC et al (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42:985–990
Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271
Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450–456
Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32:982–986
Jenisch S, Henseler T, Nair RP et al (1998) Linkage analysis of HLA markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. Am J Hum Genet 63:191–199
Lande R, Botti E, Jandus C et al (2014) The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 5:5621–5625
Meeuwis KA, de Hullu JA, Massuger LF et al (2011) Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol 91:5–11
Mrowietz U, Kragballe K, Reich K et al (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303:1–10
Mrowietz U, Steinz K, Gerdes S (2014) Psoriasis: to treat or to manage? Exp Dermatol 23:705–709
Nast A, Kopp IB, Augustin M et al (2007) S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Dtsch Dermatol Ges 5(Suppl 3):1–119
Nast A, Gisondi P, Ormerod AD et al (2015) European S3-guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – short version – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 29:2277–2294
Parrish JA, Fitzpatrick TB, Tannenbaum L et al (1974) Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. N Engl J Med 291:1207–1211
Prinz JC (2011) Autoimmune-like syndromes induced by TNF-α antagonists: infection-induced autoimmunity or autoimmune mimics? Nat Rev Rheumatol 7:429–434
Schön MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899–1912
Stuart PE, Nair RP, Ellinghaus E et al (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42:1000–1004
Tsianakas A, Mrowietz U (2016) Pruritus bei Psoriasis. Hautarzt 67:601–605
Pustular Psoriasis
Chalmers R, Hollis S, Leonardi-Bee J et al (2009) Interventions for chronic palmoplantar pustulosis. Cochrane Libr 4:1–49
Hayashi M, Fujihara K, Beder LB et al (2009) Pathogenic role of tonsillar lymphocytes in associated with HSP60/65 in pustulosis palmaris et plantaris. Auris Nasus Larynx 36:578–585
Marrakchi S, Guigue P, Renshaw BR et al (2011) Interleukin 36 receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365:620–628
Mrowietz U, van de Kerkhof PC (2011) Management or palmoplantar pustulosis. Do we need to change? Br J Dermatol 164:942–946
Seneschal J, Milpied B, Vergier B et al (2009) Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 161:1081–1088
Reiter’s Disease and Psoriatic Arthritis
Chandran V, Gottlieb A, Cook RJ et al (2009) International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 61:1235–1242
Reich K, Krüger K, Mössner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047
Ritchlin CT, Kavanaugh A, Gladman DD et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68:1387–1394
Veale DJ, Fitzgerald O (2002) Psoriatic arthritis – pathogenesis and epidemiology. Clin Exp Rheumatol 20:S27–S33
First Describer
Andrews GC, Birkmar FW, Kelly RJ (1934) Recalcitrant pustular eruptions of the palms and soles. Arch Dermatol Syph 29:548–563
Auspitz (1870) Über das Verhältnis der Oberhaut zur Papillarschicht, insbesondere bei pathologischen Zuständen der Haut. Arch Dermatol Syph 2:24–58
Barber HW (1936) Pustular psoriasis of the extremities. Guys Hosp Rep, London 86:108–119
Bjorksten B, Gustavson KH, Eriksson B et al (1978) Chronic recurrent multifocal osteomyelitis and pustulosis palmoplantaris. J Pediatr 93:227–231
Brodie BC (1818) Pathological and surgical observations on diseases of the joints. Longman, London
Crocker HR (ed) (1888) Diseases of the skin, 3rd edn. London, Lewis
Fiessinger N, Leroy E (1916) Contribution à l’étude d’une épidémie de dysenterie dans la Somme (juillet–octobre 1916). Bull Soc Méd Hôp Paris 40:2030–2069
Fournie B, Viraben R, Durroux R et al (1989) L’onychopachydermo-periostite psoriasique du gros advantage. Rev Rhum Mal Osteoartic 56:579–582
Galewsky E (1916) Über Cignolin, ein Ersatzpräparat des Chrysarobins. Dermatol Wochenschr 62:113–115
Giedion A, Holthusen W, Masel LF et al (1972) Subacute and chronic symmetrical osteomyelitis. Ann Radiol (Paris) 15:329–342
Hallopeau MH (1890) Sur eine asphyxie locale des extrémités avec polydactylite suppurative chronique et poussées éphémères de dermatite pustuleuse disséminée et symétrique. Bull Soc Fr Dermatol Syph 1:39–45
Hebra F (1872) Über einzelne während der Schwangerschaft, dem Wochenbette und bei Uterinalkrankheiten der Frauen zu beobachtende Hautkrankheiten. Wien Med Wochenschr 48:1197–1202
Köbner H (1876) Zur Aetiologie der Psoriasis. Viertelj Dermatol Syph 8:559–561
Kogoj F (1927–1928) Un cas de maladie de Hallopeau. Acta Derm Venereol 8:1–12
Königsbeck M (1917) Über stark exsudative Psoriasis mit Pustelbildung, speziell der Hände, Füsse und Nägel. Medizinische Dissertation, Universität München
Munro WJ (1898) Note sur l’ histopathologie du psoriasis. Ann Dermatol Syphiligr 9:961–967
Reiter H (1916) Über eine bisher unerkannte Spirochäteninfektion (Spirochaetosis arthritica). Dtsch Med Wochenschr 42:1535–1536
Sonozaki H, Mitsui H, Miyanaga Y et al (1981) Clinical features of 53 cases with pustulotic arthro-osteitis. Ann Rheum Dis 40:547–553
Unna PG (1916) Cignolin als Heilmittel der Psoriasis. Dermatol Wochenschr 62(116–137):150–163
Weinstein GD (1977) Methotrexate. Ann Intern Med 86:199–204
Willan R (1808) On cutaneous diseases. Vol I. Containing Ord.I Papulae. Ord. II. Squamae. Ord. III. Exanthema. Ord. IV. Bullae. Johnson, London. Order II. II. Psoriasis; dry or scaly tetter. pp 148–188 (The legend to plate VIII is called leprosy vulgaris, to plate IX leprosy Alphos. and leprosy nigricans). On page 149 Willan wrote “The name psoriasis … seems to be suitable in every respect;” and introduced with it the term
Woronoff DI (1926) Die peripheren Veränderungen der Haut um die Effloreszenzen der Psoriasis vulgaris und Syphilis corymbosa. Dermatol Wochenschr 82:249–253
von Zumbusch L (1910) Psoriasis und pustulöses Exanthem. Arch Dermatol Syphilol 99:335–346
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer-Verlag GmbH Germany, part of Springer Nature
About this entry
Cite this entry
Mrowietz, U., Prinz, J.C. (2022). Psoriasis. In: Plewig, G., French, L., Ruzicka, T., Kaufmann, R., Hertl, M. (eds) Braun-Falco´s Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-63709-8_39
Download citation
DOI: https://doi.org/10.1007/978-3-662-63709-8_39
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-63708-1
Online ISBN: 978-3-662-63709-8
eBook Packages: MedicineReference Module Medicine